Drug guidance
Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
Condition
Cancer
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combination with chemotherapy for inclusion on the MOH List of Subsidised Drugs for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma. The decision was based on the unfavourable cost-effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for toripalimab plus chemotherapy are provided in the Annex.